Abstracts Archive - Page 2546 of 2605 - ACR Meeting Abstracts

Abstract Number: 845 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Immune Complexes Upregulate the Expression of CD319 and CD229 On Plasmacytoid Dendritic Cells
Niklas Hagberg¹, Jakob Theorell², Gunnar V. Alm³, Maija-Leena Eloranta⁴, Yenan Bryceson² and Lars Rönnblom⁴, ¹Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, ⁴Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden
Background/Purpose: Patients with SLE have an activated type I interferon (IFN) system due to an ongoing IFN-alpha synthesis by plasmacytoid dendritic cells (pDCs) stimulated by…
Abstract Number: 846 • 2012 ACR/ARHP Annual Meeting
Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele up-Regulates IL10 Expression
Daisuke Sakurai¹, Jian Zhao¹, Yun Deng¹, Jennifer A. Kelly², Kathy Moser Sivils², Kenneth M. Kaufman³, Elizabeth E. Brown on behalf of PROFILE⁴, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network⁵, John B. Harley⁶, Sang-Cheol Bae⁷, Chaim O. Jacob⁸, Timothy J. Vyse⁹, Timothy B. Niewold¹⁰, Patrick M. Gaffney¹¹, Judith A. James², Robert P. Kimberly¹², Gary S. Gilkeson¹³, Diane L. Kamen¹⁴, Carl D. Langefeld¹⁵, Deh-Ming Chang¹⁶, Yeong Wook Song¹⁷, Weiling Chen¹, Jennifer M. Grossman¹, Bevra H. Hahn¹⁸ and Betty P. Tsao¹, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arthritis and Clinical Immunology, Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, ⁸Department of Medicine,, Keck School of Medicine, University of Southern California, Los Angeles, CA, ⁹Divisions of Genetics and Molecular Medicine and Immunology,, King's College London, London, United Kingdom, ¹⁰Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹³Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹⁵Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁶Headquarter, National Defense Medical Center, Taipei, ¹⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ¹⁸Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose:The established association between IL10 and multiple autoimmune diseases including SLE and elevated levels of IL-10 in SLE patients correlating with disease activity led us to fine-map…
Abstract Number: 847 • 2012 ACR/ARHP Annual Meeting
Enhanced ROCK Activation in Patients with Systemic Lupus Erythematosus
Josephine Isgro¹, Sanjay Gupta², Tanya M. Pavri², Roland Duculan², Kyriakos A. Kirou³, Jane E. Salmon⁴ and Alessandra B. Pernis², ¹Pediatric Rheumatology, Morgan Stanley Children's Hospital of New-York Presbyterian, Columbia University Medical Center, New York, NY, ²Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: The Rho GTPases, Rac and RhoA, play a key role in immune responses by regulating both cytoskeletal reorganization and gene expression. RhoA exerts many…
Abstract Number: 848 • 2012 ACR/ARHP Annual Meeting
Targeting Glycosphingolipid Biosynthesis Normalises T Lymphocyte Function in Patients with Systemic Lupus Eyrthematosus
Georgia McDonald¹, Laura Miguel¹, Cleo Hall¹, David A. Isenberg², Anthony I. Magee³, Terry Butters⁴ and Elizabeth C. Jury⁵, ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Section of Molecular Medicine, National Heart & Lung Institute, Imperial College London, London, United Kingdom, ⁴Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are characterised by hyperactive T-cells that provide help to auto-reactive B-cells. Underlying this hyperactivity are alterations in the…
Abstract Number: 849 • 2012 ACR/ARHP Annual Meeting
The Risk of Cardiovascular Disease in Systemic Sclerosis: A Population-Based Cohort Study
Ada Man¹, Yanyan Zhu², Yuqing Zhang³, Maureen Dubreuil¹, Young Hee Rho³, Christine Peloquin³, Robert W. Simms¹ and Hyon K. Choi⁴, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Recent studies show that the prevalence of subclinical atherosclerosis is increased in individuals with systemic sclerosis (SSc). An accurate understanding of cardiovascular disease…
Abstract Number: 850 • 2012 ACR/ARHP Annual Meeting
Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Masataka Kuwana¹, Tsutomu Takeuchi² and Junichi Kaburaki³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Med, Shinakasaka Clinic, Tokyo, MI, Japan
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). However, only a subset of SSc…
Abstract Number: 851 • 2012 ACR/ARHP Annual Meeting
An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis
James R. Seibold¹, Christopher P. Denton², Ekkehard Grünig³, Diana Bonderman⁴, Oliver Distler⁵, Dinesh Khanna⁶, Ulf Müller-Ladner⁷, Janet E. Pope⁸, Madelon C. Vonk⁹, Martin Doelberg¹⁰, Harbajan Chadha-Boreham¹⁰, Harald Heinzl⁴, Daniel M. Rosenberg¹⁰, Vallerie McLaughlin¹¹ and John G. Coghlan¹², ¹Scleroderma Research Consultants LLC, Avon, CT, ²Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ³University Hospital, Heidelberg, Germany, ⁴Medical University of Vienna, Vienna, Austria, ⁵Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁷Abt. f. Rheumatologie u. klinische Immunologie, Osteologie, Physikalische Therapie, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, ⁸Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁹Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁰Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ¹¹Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ¹²Royal Free Hospital, London, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality and late-stage morbidity in systemic sclerosis (SSc). Current PAH screening recommendations are consensus-based and…
Abstract Number: 852 • 2012 ACR/ARHP Annual Meeting
C-Reactive Protein Predicts Long-Term Progression of Interstitial Lung Disease and Survival in Patients with Early Systemic Sclerosis
Xiaochun Liu¹, Maureen D. Mayes¹, John D. Reveille², Emilio B. Gonzalez³, Brock E. Harper⁴, Hilda T. Draeger⁵ and Shervin Assassi⁶, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ³Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, ⁵Med/Clinical/Immunology, Univ of TX Health Sci Ctr, San Antonio, TX, ⁶Rheumatology, Univ of Texas Health Science Houston, Houston, TX
ABSTRACT:Background/Purpose: The currently available clinical markers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In…
Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Robert Terkeltaub¹, Robert R. Evans², Steven P. Weinstein³, Richard Wu⁴ and H. Ralph Schumacher⁵, ¹Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ²Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]
Abstract Number: 814 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study
Chang-Fu Kuo¹, Matthew J. Grainge², Lai-Chu See³, Kuang-Hui Yu⁴, Shue-Fen Luo⁴, Ana M. Valdes⁵, Weiya Zhang¹ and Michael Doherty⁶, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom, ³Department of Public Health, College of Medicine, Chang Gung University, Chang Gung University, Taoyuan, Taiwan, ⁴Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Gout has long been recognised to cluster within families. However, formal evidence for familial aggregation is scant and discordant and the magnitude of any…
Abstract Number: 815 • 2012 ACR/ARHP Annual Meeting
Exploratory Analysis of Radiographic Change in Patients Treated with Intensive Urate-Lowering Therapy
Nicola Dalbeth¹, Anthony Doyle², Fiona M. McQueen³, John S. Sundy⁴ and Herbert S. B. Baraf⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁴Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ⁵Arthritis & Rheumatism Associates, Wheaton, MD
Background/Purpose: In patients with gout, tophi are strongly associated with radiographic damage. Effective urate-lowering therapy (ULT) reduces tophus size. However, no studies to date have…
Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…
Abstract Number: 817 • 2012 ACR/ARHP Annual Meeting
Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan
Robert D. Goldfien¹, Michele S. Ng², Goldie M. Yip², Alice Hwe², Alice Pressman³ and Andy L. Avins³, ¹Kaiser Permanente, Richmond, CA, ²Pharmacy, Kaiser Permanente, Oakland, CA, ³Division of Research, Kaiser Permanente, Oakland, CA
Background/Purpose: Effective treatment for recurrent gout has been hampered by a number of problems including outdated treatment approaches, a failure to treat to target, and…
Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting
Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Robert J. Noveck¹, Zongyao Wang¹, Ann Forsthoefel¹, Kristina Sigmon², Pauliana C. Hall³, John C. Keogh⁴ and John S. Sundy², ¹Duke Clinical Research Unit, Duke University Medical Center, Durham, NC, ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ³PCH Integrated Regulatory Services, Inc., Laguna Niguel, CA, ⁴Keogh Medical Writing, Philadelphia, PA
Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…
Abstract Number: 819 • 2012 ACR/ARHP Annual Meeting
Trajectories of Change in Physical Function: Effects On Fractures and Mortality
Kamil E. Barbour¹, Li-Yung Lui², Deborah E. Barnes³, Kristine E. Ensrud⁴, Anne B. Newman⁵, Kristine Yaffe³, Steven R. Cummings⁶ and Jane A. Cauley⁵, ¹Centers for Disease Control and Prevention, Atlanta, GA, ²California Pacific Medical Center, San Francisco, CA, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, San Francisco, CA, ⁴University of Minnesota and Minneapolis VAHS, Minneapolis, MN, Minneapolis, MN, ⁵Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁶San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA
Background/Purpose: Prior studies have identified poor physical function as a risk factor for fractures and mortality. However, these studies did not consider change in physical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].